Telesis Bio
Telesis Bio empowers researchers with the tools to rapidly and securely design, code, and create synthetic DNA and mRNA.
Telesis Bio empowers researchers with the tools to rapidly and securely design, code, and create synthetic DNA and mRNA.
Telesis Bio is a biotechnology startup based in the United States that focuses on empowering researchers to accelerate the creation of novel synthetic biology solutions to address global challenges. The company's breakthrough automation solutions for biological synthesis, combined with its expertise in DNA biology, enable rapid, accurate, and reproducible writing of DNA and mRNA for a wide range of biological applications. Its technology is being leveraged by innovators worldwide to overcome bottlenecks in synthetic biology workflows and advance the discovery of cutting-edge solutions for health and technology.
Telesis Bio boasts a strong network of collaborators, including premier academic research institutions, emerging startups, and nearly all of the Top 25 Biopharma companies. The company's collaborations have resulted in pioneering advances, such as novel infectious disease vaccines, precision immunotherapy for cancer, antibody therapeutics, as well as engineered meat substitutes and sustainable cellular agricultural products.
Founded in 2013, Telesis Bio recently secured a major $74.20M post-IPO equity investment on 31 May 2023. The investment was led by BroadOak Capital Partners, Northpond Ventures, Novalis LifeSciences, and M-185 Corporation, showcasing the strong confidence and support from notable investors in the industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $74.20M | 4 |
|
31 May 2023 |
No recent news or press coverage available for Telesis Bio.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
